BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
Enhanced cryo–electron microscopy promises to bring previously elusive proteins into view.
AI-guided redesign of protein alphabet in bacteria could unlock new ways to build synthetic organisms.